CEO Marc Beer

Renovia Inc. will move forward with many new products for pelvic floor disorders. This is after it closed a recent Series B round financing with $32 million along with $10 million in venture debt.


The med-tech company that was co-founded by former Aegerion pharmaceuticals CEO marc beer is presently based in Boston. Renovia is creating an array of diagnostic and therapeutic products for the treatment of pelvic floor disorders such as urinary incontinence.


Researchers estimate that about 250 million women worldwide suffer urinary incontinence. Leva which is Renovia’s first product received approval from the FDA in April.


The series b funding round was led by New York-based perceptive advisors and Missouri based ascension ventures.


The Longwood Fund which was one of the early Renovia investors also joined the series b round. The funding is expected to be used in the testing of four more of Renovia’s diagnostic products including a new generation of the Leva device.


In a statement, Renovia’s CEO Marc beer said that they were happy to have the support from an elite group of healthcare investors who shared his company’s vision of better diagnosis, treatment, and improvement of the lives of millions of women affected by pelvic floor disorders.


He further said that by combining their innovative and proprietary sensor technologies with a digital health platform they would be giving clients crucial data that will inform treatment options and provide a better understanding of pelvic floor disorders.


Marc beer has over 20 years of experience in pharmaceuticals, biotechnology, and diagnostics.


In early 2000, Marc became founding CEO of Viacell, a biotechnology company that was dedicated tote collection and preservation of umbilical cord blood stem cells. Under marc’s prudent leadership the company quickly grew into a robust commercial


organization with hundreds of employees before being acquired by PerkinElmer in 2007.

Marc also served on the board of directors at Erytech Pharma while he was the CEO at Viacell. Before Viacell, he held various positions most notably as vice president of global marketing at Genzyme where he oversaw the launch of many products that were aimed at addressing rare diseases globally.


Marc is a former member of the mass life science board of the Commonwealth of Massachusetts and is the chairman of the compensation committee of GoodStart Genetics Inc. that was recently bought up by InVitae.


He is a member of the audit committee of the Minerva Neurosciences Inc. marc has a BS that he got from Miami University in Ohio. Learn more :